Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 536

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12

Kreis, Henri, Cisterne, Jean-Marc, Land, Walter, Wramner, Lars, Squifflet, Jean-Paul, Abramowicz, Daniel, Campistol, Josep M., Morales, Jos??-Maria, Grinyo, Jos??-Maria, Mourad, Georges, Berthoux, Fran??ois-Claude, Brattstr??m, Christina, Lebranchu, Yvon, Vialtel, Paul·2000·Transplantation

Abstract

INTRODUCTION: A previous trial in renal transplantation comparing sirolimus (rapamycin) to cyclosporine (CsA) in a triple-drug therapy regimen with azathioprine and corticosteroids found that the incidence of acute rejection was similar (approximately 40%) with a trend for better renal function with sirolimus. METHODS: In 14 European centers, first cadaveric renal allograft recipients were randomized to receive sirolimus (n = 40) or CsA (n = 38) in an open-label design. All patients received corticosteroids and mycophenolate mofetil 2 g/day. Sirolimus and CsA were concentration controlled; trough levels of mycophenolic acid and prednisolone were also measured. RESULTS: At 12 months, graft survival (92.5% sirolimus vs. 89.5% CsA), patient survival (97.5% sirolimus vs. 94.7% CsA), and the incidence of biopsy-proven acute rejection (27.5% sirolimus vs. 18.4% CsA) were not statistically different. The use of antibodies to treat suspected rejection episodes was also similar (7.5% sirolimus vs. 5.3% CsA). More sirolimus patients received bolus steroid therapy (20 vs. 11, P = 0.068). From month 2 onward, the calculated glomerular filtration rate was consistently higher in sirolimus-treated patients. The adverse events reported more frequently with sirolimus were thrombocytopenia (45% vs. 8%) and diarrhea (38% vs. 11%). In the CsA group, increased creatinine (18% vs. 39%), hyperuricemia (3% vs. 18%), cytomegalovirus infection (5% vs. 21%), and tremor (5% vs. 21%) were observed significantly more often. DISCUSSION: Patient and graft survival and the incidence of biopsy-proven acute rejection at 12 months were comparable between sirolimus and CsA, whereas safety profiles were different. These data suggest that sirolimus may be used as primary therapy for the prevention of acute rejection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-200004150-00009

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 536

Metadata

Authors
Kreis, H., Cisterne, J.-M., Land, W., Wramner, L., Squifflet, J.-P., Abramowicz, D., Campistol, J. M., Morales, J.-M., Grinyo, J.-M., Mourad, G., Berthoux, F.-C., Brattstr??m, C., Lebranchu, Y., & Vialtel, P.
Venue
Transplantation
Published
2000-04
Volume
69
Issue
7
Pages
1252-1260
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2123940335
Cited by
536
References
15
FWCI
31.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12. https://app.cochat.ai/papers/10.1097/00007890-200004150-00009
The paper
Kreis, H., Cisterne, J.-M., Land, W., Wramner, L., Squifflet, J.-P., Abramowicz, D., Campistol, J. M., Morales, J.-M., Grinyo, J.-M., Mourad, G., Berthoux, F.-C., Brattstr??m, C., Lebranchu, Y., & Vialtel, P. (2000). SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12. Transplantation. https://doi.org/10.1097/00007890-200004150-00009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.